Florian H. Heidel

Leipziger Str. 44
Magdeburg, ST 39120, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 199 publications

Value of functional iron parameters in diagnostic re-assessment of MPN: refinement of iron-deficiency markers by zinc protoporphyrin (ZPP).

Value of functional iron parameters in diagnostic re-assessment of MPN: refinement of iron-deficiency markers by zinc protoporphyrin (ZPP).

Journal: Annals of hematology
Published: April 16, 2026

Clonal Hematopoiesis Instructs Maladaptive Tissue Repair to Promote Fibrosis.

Clonal Hematopoiesis Instructs Maladaptive Tissue Repair to Promote Fibrosis.

Journal: bioRxiv : the preprint server for biology
Published: April 03, 2026

Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach.

Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach.

Journal: Leukemia
Published: March 20, 2026

Type I interferon-activated NK cells control polycythemia vera in vivo.

Type I interferon-activated NK cells control polycythemia vera in vivo.

Journal: Blood
Published: March 09, 2026

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.

Journal: Future oncology (London, England)
Published: March 07, 2026

From Recommendation to Implementation: Clinical Outcomes of a Single-Center Molecular Tumor Board.

From Recommendation to Implementation: Clinical Outcomes of a Single-Center Molecular Tumor Board.

Journal: Targeted oncology
Published: February 28, 2026

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib.

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib.

Journal: Blood advances
Published: February 27, 2026

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

Journal: Blood advances
Published: February 27, 2026

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

Journal: Cancer
Published: February 19, 2026

MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms.

MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms.

Journal: Leukemia
Published: February 14, 2026

Primary Myelofibrosis (PMF)-The German ONKOPEDIA Guideline 2025.

Primary Myelofibrosis (PMF)-The German ONKOPEDIA Guideline 2025.

Journal: International journal of cancer
Published: February 07, 2026

The German ONKOPEDIA Guideline for Myelofibrosis in 2025-Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO).

The German ONKOPEDIA Guideline for Myelofibrosis in 2025-Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO).

Journal: International journal of cancer
Published: February 07, 2026
Showing 1-12 of 199

Last Updated: 09/26/2026